Trabectedin Improves PFS in Advanced Leiomyosarcoma
Adding trabectedin to doxorubicin doubled the median progression-free survival.
Sarcoma
Carboplatin Deemed Acceptable Replacement for Actinomycin-D in Ewing Sarcoma
There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.
High-Dose Ifosfamide Bests Topotecan-Cyclophosphamide in Relapsed/Refractory Ewing Sarcoma
Ifosfamide improved event-free and overall survival.
No PFS Benefit With Carotuximab in Advanced Angiosarcoma
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Fyarro Now Available for Malignant Perivascular Epithelioid Cell Tumor
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Sarcoma Symptom Management, QOL, Communication Improved With Journaling
Crossover randomized study sought to determine if structured journaling could lead to improved quality of life, symptom management, and communication with the clinical care team.
Treatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma
Young adults were more likely to receive chemotherapy.
Triplet Deemed New Standard Care for Relapsed or Refractory Rhabdomyosarcoma
Adding temozolomide to vincristine and irinotecan improved survival.
CMB305 Vaccine Demonstrates Activity But Doesn’t Improve Survival in Soft-Tissue Sarcomas
CMB305 increased antibody responses and NY-ESO-1-specific T-cell responses.
Nanoparticle Albumin-Bound mTOR Inhibitor Gets Priority Review for Ultra-Rare Sarcoma
Nab-sirolimus is an mTOR inhibitor bound to human albumin.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Sarcoma
Loading... 
Loading...